Literature DB >> 830359

Comparison of a vasoconstrictor and a vasodilator in pharmacoangiography of bone and soft-tissue tumors.

L Ekelund, S Laurin, A Lunderquist.   

Abstract

The pharmacoangiographic effect of a vasoconstrictor (angiotensin) and a vasodilator (tolazoline) was compared in 18 patients with bone and soft-tissue tumors. Angiotensin was found to be the drug of choice in increasing diagnostic information on angiography. Ten to 15 mug of angiotensin seems to be a convenient dose in the axillary, iliac, and femoral arteries.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 830359     DOI： 10.1148/122.1.95

Source DB:  PubMed          Journal:  Radiology        ISSN： 0033-8419            Impact factor:   11.105


  4 in total

1.  Perfusion CT assessment of tissue hemodynamics following hepatic arterial infusion of increasing doses of angiotensin II in a rabbit liver tumor model.

Authors:  Kenneth C Wright; Murali K Ravoori; Katherine A Dixon; Lin Han; Sheela P Singh; Ping Liu; Sanjay Gupta; Valen E Johnson; Zuxing Kan; Vikas Kundra
Journal:  Radiology       Date:  2011-06-01       Impact factor: 11.105

2.  Modification of tumor blood flow and enhancement of therapeutic effect of ACNU on experimental rat gliomas with angiotensin II.

Authors:  K Tokuda; H Abe; T Aida; S Sugimoto; S Kaneko
Journal:  J Neurooncol       Date:  1990-06       Impact factor: 4.130

3.  Late recurrence of giant-cell tumor of bone: pharmacoangiographic evaluation.

Authors:  S Laurin; L Ekelund; B Persson
Journal:  Skeletal Radiol       Date:  1980       Impact factor: 2.199

4.  Angiotensin II increases gene expression after selective intra-arterial adenovirus delivery in a rabbit model assessed using in vivo SSTR2-based reporter imaging.

Authors:  Sheela P Singh; Murali K Ravoori; Katherine A Dixon; Lin Han; Sanjay Gupta; Rajesh Uthamanthil; Kenneth C Wright; Vikas Kundra
Journal:  EJNMMI Res       Date:  2016-03-17       Impact factor: 3.138
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.